Table 2.
CTL vs LC | Benign vs LC | BC vs LC | |||||||
---|---|---|---|---|---|---|---|---|---|
Predicted | Predicted | Predicted | |||||||
Group | CTL | LC | Group | Benign | LC | Group | BC | LC | |
Actual | CTL | 9 | 1 | Benign | 28 | 12 | BC | 10 | 7 |
LC | 1 | 9 | LC | 1 | 32 | LC | 2 | 31 | |
Error | 0.1 | Error | 0.178 | Error | 0.18 | ||||
Sensitivity | 90% | Sensitivity | 96.97% | Sensitivity | 93.94% | ||||
Specificity | 90% | Specificity | 70% | Specificity | 58.82% | ||||
CCA vs LC | CRC vs LC | EC vs LC | |||||||
Predicted | Predicted | Predicted | |||||||
Group | CCA | LC | Group | CRC | LC | Group | EC | LC | |
Actual | CCA | 18 | 7 | CRC | 12 | 10 | EC | 12 | 2 |
LC | 1 | 32 | LC | 1 | 32 | LC | 1 | 32 | |
Error | 0.138 | Error | 0.2 | Error | 0.064 | ||||
Sensitivity | 96.97% | Sensitivity | 96.97% | Sensitivity | 96.97% | ||||
Specificity | 72% | Specificity | 54.55% | Specificity | 85.71% | ||||
GC vs LC | |||||||||
Predicted | |||||||||
Group | GC | LC | |||||||
Actual | GC | 38 | 9 | ||||||
LC | 1 | 32 | |||||||
Error | 0.125 | ||||||||
Sensitivity | 96.97% | ||||||||
Specificity | 80.85% |
Sensitivity = number of true positives / (number of true positives + number of false negatives); Specificity = number of true negatives / (number of true negatives + number of false positives); CTL, healthy controls; LC, lung cancer; BC, bladder cancer; CCA, cervical cancer; CRC, colorectal cancer; EC, esophageal cancer; GC, gastric cancer. All test sets except for the test set 1 (CTL vs LC) compares all lung cancer patients to benign diseases or other cancers.